EMA starts rolling review of Moderna’s Omicron-targeting vaccine, as well as Pfizer-BioNTech rival
The vaccines have been adapted to target the Omicron variant, which has been the dominant variant globally since the beginning of the year
The European Medicines Agency (EMA) has initiated a rolling review of Moderna’s variant-adapted COVID-19 vaccine, which the company says targets the Omicron variant as well as the original strain first detected in China.
The US-based vaccine maker said last week that the so-called bivalent vaccine produced a better immune response against Omicron than the original shot.
The EMA also started a rolling review of the mRNA, variant-adapted vaccine created by Pfizer and BioNTech last Wednesday. A rolling review is a regulatory tool that EMA uses to speed up the assessment of a promising medicine or vaccine during a public health emergency. Here, the regulator assesses the data as it becomes available, and the process continues until there is enough data for a formal marketing application.
Omicron cases have been surging across the world, fuelled by the highly transmissible BA.4 and BA.5 sub-variants. The US Centers for Disease Control and Prevention (CDC) said that these sub lineages make up about 8.3% and 13.3% of cases respectively in the US, as of June 11. BA.4 and BA.5 have also been designated variants of concern in Europe, however the BA.2.12.1 sub-variant remains the most prevalent.
According to a study published recently in Nature, people who were infected with Omicron early in its spread may be vulnerable to reinfection by later sub-variants due to mutations that have developed.
Vaccinated patients with Omicron BA.1 breakthrough infections developed antibodies that could neutralise that virus plus the original SARS-CoV-2 virus, but mutations in the BA.2.12.1, BA.4, and BA.5 sub lineages allow them to evade antibody protection.
Several international bodies have raised concerns over the global relaxation of COVID rules in the last six months, warning that cases are likely to surge again as autumn and winter close in.
In May, the White House announced that America could record as many as 100 million Covid-19 infections in the latter half of this year, while WHO Director-General Tedros Adhanom Ghebreyesus warned the pandemic was ‘certainly not over’.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance